https://orcid.org/0000-0002-7077-7937
References
- Vermorken JB, Mesia R, Rivera F, et al. Platinum-Based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–1127.
- Lala M, Chirovsky D, Cheng JD, et al. Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): a systematic literature review. Oral Oncol. 2018;84:108–120.
- Bentzen JKD, Kristensen CA, Overgaard M, et al. A non platinum regimen for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck region. Results from an extended phase II study with paclitaxel and capecitabine. Front Oncol. 2018;8:243–243.
- Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent Squamous-Cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867.
- Cohen EEW, Souliéres D, Tourneau CL, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–167.
- Carlsen AH, Eriksen JG, Godballe C, et al. Impact of age, comorbidity, and WHO performance status on delay of treatment in patients undergoing fast-track work-up for head and neck cancer. J Geriatric Oncol. 2019;10(2):259–264.
- Seymour L, Bogaerts J, Perrone A, RECIST working group, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e152.
- Overgaard J, Jovanovic A, Godballe C, et al. The danish head and neck cancer database. Clin Epidemiol. 2016;8:491–496.
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.
- Bøje CR, Dalton SO, Primdahl H, et al. Evaluation of comorbidity in 9388 head and neck cancer patients: a national cohort study from the DAHANCA database. Radiother Oncol. 2014;110(1):91–97.
- Soyano AE, Dholaria B, Marin-Acevedo JA, et al. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies. J Immunother Cancer. 2018;6(1):129–129.
- Kim S, Koh J, Kwon D, et al. Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. Euro J Cancer. 2017;75:141–149. (1990)
- Pinato DJ, Shiner RJ, White SDT, et al. Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy. Oncoimmunology. 2016;5(9):e1213934-e1213934.
- Frank MS, Bødtger U, Høegholm A, et al. Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression. Lung Cancer. 2020;149:23–32.